99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis

Completed 142 enrolled Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis. Therefore, the investigators try to investigate the effects of 99Tc-MDP,alendronate sodium in postmenopausal women with DTC under TSH suppression and osteoporosis.

Timeline

Start: 2015-01
Primary completion: 2019-12-30
Completion: 2019-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	99Tc-MDP	Unknown	15 mg	Intravenous
Comparator	Alendronic Acid	Small molecule	70 mg	Oral

99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis

Summary

Timeline

Drugs

Indications